Simian Foamy Virus Transmission to Humans
NCT03225794 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600
Last updated 2025-09-22
Summary
About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after the initial contact that resulted in interspecies transmission. However, knowledge of the initial stages of the emergence of viruses and associated diseases is still limited in many cases. Microbiological monitoring in populations at risk of transmission would provide insights into the initiation and early stages of the emergence process.
Nonhuman primates (NHPs) share many genetic, physiological, and microbiological features with humans, and are potential sources of many infectious agents. This has been demonstrated for several simian retroviruses. HIV-1 and 2 are believed to have originated from chimpanzee and mangabey viruses, respectively, found in Central and West Africa. The current distribution of the various molecular subtypes of the HTLV-1 oncogenic retrovirus in Africa is mainly the result of numerous instances of interspecies transmission of STLV-1from NHP species in the distant past.
Foamy viruses belong to the Retrovidae family and the Spumavirus genus. They are complex exogenous retroviruses and are very common in many animal species, including primates, cats, cattle, and horses, in which they cause persistent infections.
The first aim of the work is to study the epidemiological and molecular aspects of the transmission of foamy viruses from monkeys to humans in populations at risk, such as the inhabitants (especially hunters) in the villages of the dense forests of southern Cameroon. It is an area in which NHPs are still very common, with a great diversity of species. The investigators have already shown that the prevalence of foamy viruses is very high in these monkeys and great apes (gorillas and chimpanzees). Contact between these monkeys and the villagers is very frequent, mainly during hunting. The second aim of the project is to study the clinical and biological features of infected people and investigate intrafamilial transmission from infected index cases.
Conditions
- Simian Foamy Virus Infection (Disorder)
Interventions
- DIAGNOSTIC_TEST
-
Simian foamy virus Infection
Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
Sponsors & Collaborators
-
Institut Pasteur
lead INDUSTRY
Principal Investigators
-
Antoine GESSAIN, MD · Institut Pasteur
Eligibility
- Min Age
- 5 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-11-01
- Primary Completion
- 2026-12-31
- Completion
- 2027-12-31
Countries
- Cameroon
Study Locations
More Related Trials
-
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
NCT00215267 ·Status: COMPLETED ·Phase: NA
-
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
NCT05466630 ·Status: COMPLETED ·Phase: NA
-
Diagnostic of Puumala Virus Infection in France
NCT02455375 ·Status: COMPLETED
-
Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.
NCT04505046 ·Status: UNKNOWN
-
Screen and Treat Implementation for HAT Control
NCT05645822 ·Status: WITHDRAWN
-
Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes
NCT06981442 ·Status: RECRUITING ·Phase: NA
-
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
NCT00146627 ·Status: COMPLETED ·Phase: PHASE3
-
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
NCT03356665 ·Status: COMPLETED ·Phase: NA
-
Schistosoma Mansoni Morbidity in Children Aged 1-5 Years
NCT01901484 ·Status: COMPLETED ·Phase: PHASE2
-
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
NCT04672577 ·Status: NOT_YET_RECRUITING
-
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis
NCT02734186 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
NCT01541631 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
NCT00906880 ·Status: COMPLETED ·Phase: PHASE4
-
Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact
NCT02194712 ·Status: COMPLETED
-
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
NCT01593722 ·Status: COMPLETED ·Phase: PHASE4
-
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France
NCT04810741 ·Status: COMPLETED
-
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
NCT02755324 ·Status: COMPLETED ·Phase: NA
-
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
NCT06698510 ·Status: RECRUITING
-
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
NCT03784391 ·Status: COMPLETED
-
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
NCT05256017 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Research for Angiostrongylus Cantonensis and Costaricensis in French West Indies and French Guiana
NCT03378882 ·Status: UNKNOWN
-
Immunochromatography Versus Microscopy for Diagnosis of Entamoeba Histolytica/Dispar Infection.
NCT04759937 ·Status: UNKNOWN
-
West Nile Virus Natural History
NCT00138463 ·Status: COMPLETED
-
An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
NCT02806232 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
NCT00127504 ·Status: COMPLETED ·Phase: PHASE2